226 related articles for article (PubMed ID: 30339275)
1. The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice.
Toffoli G; Innocenti F; Polesel J; De Mattia E; Sartor F; Dalle Fratte C; Ecca F; Dreussi E; Palazzari E; Guardascione M; Buonadonna A; Foltran L; Garziera M; Bignucolo A; Nobili S; Mini E; Favaretto A; Berretta M; D'Andrea M; De Paoli A; Roncato R; Cecchin E
Clin Pharmacol Ther; 2019 Apr; 105(4):994-1002. PubMed ID: 30339275
[TBL] [Abstract][Full Text] [Related]
2. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
[TBL] [Abstract][Full Text] [Related]
3. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
4. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
5.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
[TBL] [Abstract][Full Text] [Related]
6. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
7. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
[TBL] [Abstract][Full Text] [Related]
8. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
Li GY; Duan JF; Li WJ; Liu T
J Cancer Res Ther; 2016; 12(2):782-6. PubMed ID: 27461651
[TBL] [Abstract][Full Text] [Related]
9. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
Terrazzino S; Cargnin S; Del Re M; Danesi R; Canonico PL; Genazzani AA
Pharmacogenomics; 2013 Aug; 14(11):1255-72. PubMed ID: 23930673
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
12. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
[TBL] [Abstract][Full Text] [Related]
13. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis.
Fariman SA; Jahangard Rafsanjani Z; Hasanzad M; Niksalehi K; Nikfar S
Value Health Reg Issues; 2023 Sep; 37():71-80. PubMed ID: 37329861
[TBL] [Abstract][Full Text] [Related]
14. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
[TBL] [Abstract][Full Text] [Related]
15. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
[TBL] [Abstract][Full Text] [Related]
16. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
[TBL] [Abstract][Full Text] [Related]
17. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Amstutz U; Offer SM; Sistonen J; Joerger M; Diasio RB; Largiadèr CR
Clin Cancer Res; 2015 May; 21(9):2038-44. PubMed ID: 25655103
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]